VPS16
Basic information
Region (hg38): 20:2840703-2866732
Links
Phenotypes
GenCC
Source:
- isolated dystonia (Limited), mode of inheritance: AR
- dystonia 30 (Strong), mode of inheritance: AD
- dystonia 30 (Limited), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Dystonia 30 | AD/AR | Neurologic | Response to deep brain stimulation has been described | Neurologic | 27174565; 32808683; 33482438 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (2 variants)
- Dystonia 30 (2 variants)
- VPS16-associated disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the VPS16 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 11 | |||||
missense | 73 | 77 | ||||
nonsense | 4 | |||||
start loss | 0 | |||||
frameshift | 5 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 1 | 1 | 2 | |||
non coding | 10 | 13 | ||||
Total | 3 | 5 | 80 | 10 | 15 |
Highest pathogenic variant AF is 0.00000657
Variants in VPS16
This is a list of pathogenic ClinVar variants found in the VPS16 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
20-2840754-C-T | Benign (May 17, 2021) | |||
20-2840769-C-G | Uncertain significance (Mar 01, 2023) | |||
20-2840779-A-G | Inborn genetic diseases | Uncertain significance (Oct 26, 2021) | ||
20-2840825-C-G | Uncertain significance (Oct 01, 2022) | |||
20-2840882-C-T | Benign (May 26, 2021) | |||
20-2840955-C-T | Benign (May 17, 2021) | |||
20-2859715-G-A | Likely benign (Mar 01, 2022) | |||
20-2859795-G-A | Dystonia 30 | Uncertain significance (-) | ||
20-2859801-C-T | Inborn genetic diseases | Uncertain significance (Oct 10, 2023) | ||
20-2860052-A-T | Dystonia 30 | Likely pathogenic (-) | ||
20-2860067-C-A | Dystonia 30 | Pathogenic (Apr 30, 2021) | ||
20-2860109-C-G | Likely benign (Feb 01, 2023) | |||
20-2860110-G-A | Inborn genetic diseases | Uncertain significance (Nov 08, 2022) | ||
20-2860117-A-C | Inborn genetic diseases | Uncertain significance (Jun 18, 2021) | ||
20-2860127-C-T | Benign (May 05, 2021) | |||
20-2860144-G-T | Inborn genetic diseases | Uncertain significance (Feb 26, 2024) | ||
20-2860242-AAGAGTGGACCCGTGG-GAGAGC | Dystonia 30 | Pathogenic (Oct 20, 2021) | ||
20-2860283-G-A | Benign (May 05, 2021) | |||
20-2860284-G-A | Inborn genetic diseases | Uncertain significance (Jan 01, 2023) | ||
20-2860320-G-A | Uncertain significance (Dec 28, 2023) | |||
20-2860365-A-C | Inborn genetic diseases | Uncertain significance (Jul 06, 2021) | ||
20-2860366-A-G | Inborn genetic diseases | Uncertain significance (May 02, 2024) | ||
20-2860454-G-A | Likely benign (Aug 01, 2024) | |||
20-2860486-T-C | Inborn genetic diseases | Uncertain significance (Nov 30, 2022) | ||
20-2860490-C-T | Likely benign (Mar 01, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
VPS16 | protein_coding | protein_coding | ENST00000380445 | 24 | 26030 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.27e-15 | 0.988 | 125697 | 0 | 51 | 125748 | 0.000203 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.823 | 458 | 510 | 0.897 | 0.0000321 | 5454 |
Missense in Polyphen | 158 | 193.89 | 0.81488 | 1979 | ||
Synonymous | 0.861 | 184 | 199 | 0.922 | 0.0000120 | 1654 |
Loss of Function | 2.62 | 32 | 52.5 | 0.609 | 0.00000298 | 555 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000384 | 0.000384 |
Ashkenazi Jewish | 0.0000993 | 0.0000992 |
East Asian | 0.000217 | 0.000217 |
Finnish | 0.000139 | 0.000139 |
European (Non-Finnish) | 0.000274 | 0.000264 |
Middle Eastern | 0.000217 | 0.000217 |
South Asian | 0.0000653 | 0.0000653 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Plays a role in vesicle-mediated protein trafficking to lysosomal compartments including the endocytic membrane transport and autophagic pathways. Believed to act as a core component of the putative HOPS and CORVET endosomal tethering complexes which are proposed to be involved in the Rab5-to-Rab7 endosome conversion probably implicating MON1A/B, and via binding SNAREs and SNARE complexes to mediate tethering and docking events during SNARE-mediated membrane fusion. The HOPS complex is proposed to be recruited to Rab7 on the late endosomal membrane and to regulate late endocytic, phagocytic and autophagic traffic towards lysosomes. The CORVET complex is proposed to function as a Rab5 effector to mediate early endosome fusion probably in specific endosome subpopulations (PubMed:11382755, PubMed:23351085, PubMed:24554770, PubMed:25266290, PubMed:25783203). Required for recruitment of VPS33A to the HOPS complex (PubMed:23901104). Required for fusion of endosomes and autophagosomes with lysosomes; the function is dependent on its association with VPS33A but not VPS33B (PubMed:25783203). The function in autophagosome-lysosome fusion implicates STX17 but not UVRAG (PubMed:24554770). {ECO:0000269|PubMed:23901104, ECO:0000269|PubMed:24554770, ECO:0000269|PubMed:25783203, ECO:0000305|PubMed:11382755, ECO:0000305|PubMed:23351085, ECO:0000305|PubMed:25266290, ECO:0000305|PubMed:25783203}.;
- Pathway
- Ebola Virus Pathway on Host;Ebola Virus Pathway on Host
(Consensus)
Recessive Scores
- pRec
- 0.111
Intolerance Scores
- loftool
- 0.817
- rvis_EVS
- -0.9
- rvis_percentile_EVS
- 10.14
Haploinsufficiency Scores
- pHI
- 0.303
- hipred
- N
- hipred_score
- 0.415
- ghis
- 0.565
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- K
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.890
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Vps16
- Phenotype
- behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); muscle phenotype;
Gene ontology
- Biological process
- intracellular protein transport;vacuole organization;endosome to lysosome transport;endosomal transport;regulation of vacuole fusion, non-autophagic;regulation of SNARE complex assembly;autophagosome maturation
- Cellular component
- lysosome;lysosomal membrane;endosome;early endosome;late endosome;autophagosome;clathrin-coated vesicle;axon;HOPS complex;late endosome membrane;neuronal cell body;recycling endosome
- Molecular function
- actin binding;protein binding;actin filament binding